CClinicalTrials.gg
CompletedNCT06182527HypoCGMUpdated Dec 10, 2025

Relevance of Reactive Hypoglycemia During an OGTT in Everyday Life Using Continuous Glucose Measurement

An interventional study of Free Style Libre Pro IQ in Hypoglycemia, Reactive, sponsored by University of Ulm. Completed at 1 site in Germany. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-10.

Sponsored by University of Ulm · Not applicable, Interventional, and Screening

Phase
Not applicable
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This research project aims to investigate the everyday relevance of reactive hypoglycemia (hypoglycemia after a glucose load) in the oral glucose tolerance test (OGTT). Therefore, blood glucose profiles in everyday life will be examined using continuous glucose measurement (Free Style Libre PRO IQ system) over a period of 14 days in affected persons.

Read the detailed description

The aim of this analysis is to examine people who underwent an OGTT due to various endocrinological and metabolic issues and developed reactive hypoglycemia, defined as a drop in blood glucose \<70mg/dl during the course of the test. During OGTT routine laboratory testing will be performed as part of routine clinical practice. In order to investigate the occurrence and perception of hypoglycaemia in the everyday lives of those affected, their blood glucose profiles will be recorded and evaluated over a period of 14 days.

In addition, the perception of (suspected) hypoglycemia and counteraction will be documented. Anthropometric data will be recorded and a bioelectrical impedance analysis performed to check a correlation with the body composition. Subjects will be recruited via the endocrinology outpatient clinic as part of medical care. To date, very little CGM data are available on the frequency and extent of reactive hypoglycemia in the everyday lives of people without diabetes mellitus. Therefore, 20 subjects with hypoglycemia in the OGTT will be included in this exploratory pilot study for hypothesis generation in order to investigate the occurrence and perception of hypoglycemia in everyday life.

02

Conditions studied

  • Hypoglycemia, Reactive

Browse trials for

Keywords

  • Reactive Hypoglycemia
  • Oral glucose tolerance test
  • Continuous glucose monitoring
03

In context

Hypoglycemia

640 studies on the registry are indexed under Hypoglycemia; 86 are open to participants now.

This study's enrollment of 21 is below the median of 29 across 471 interventional studies indexed under Hypoglycemia.

Browse Hypoglycemia studies →

Lead sponsor

University of Ulm is the lead sponsor of 141 studies on the registry; 26 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • hypoglycemia during a 75 g oral glucose tolerance test defined as glucose level below 70 mg/dl at timepoint 180 min.
  • written consent

Exclusion criteria

Exclusion Criteria:

  • diabetes mellitus
  • use of medication interfering with glucose metabolism (steroid, antidiabetic medications)
  • surgery of upper GI-tract
  • known plaster allergies
  • any other clinical condition that would endanger participants safety or question scientific success according to the physicians opinion
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    CGM Group

    Every participant receives a Free Style Libre Pro IQ sensor for 14 days. Glucose levels will be recorded. In addition perception of hypoglycemia and counter action will be assessed.

    Device: Free Style Libre Pro IQ

Interventions

  • DeviceFree Style Libre Pro IQ

    Every participant receives a Free Style Libre Pro IQ sensor for 14 days. Glucose levels will be recorded.

06

What researchers measure

Primary outcomes

  1. Occurrence of hypoglycemia

    Occurrence of glucose levels below 70 mg/dl assessed by CGM.

    Time frame: 14 days

  2. Frequency of hypoglycemia

    Number of glucose levels below 70 mg/dl assessed by CGM.

    Time frame: 14 days

  3. Severity of hypoglycemia

    Non-severe hypoglycemia defined as glucose levels \< 70 mg/dl but \>= 54mg/dl; severe hypoglycemia defined as glucose levels \< 54mg/dl assessed by CGM.

    Time frame: 14 days

Secondary outcomes

  1. Time of occurence of hypoglycemia

    Occurence of hypoglycemia during day or night time and correspondence to food intake assessed by CGM.

    Time frame: 14 days

  2. Perception of hypoglycemia

    Incidence of typical symptoms of hypoglycemia perceived by the participant, documented in a protocol with free-text fields handed out to the participant during 1st study visit.

    Time frame: 14 days

  3. Time in predefined glucose ranges

    Time spent in the following glucose ranges: time above range: \>140mg/dl; time in range: 71-140mg/dl; time below range: \<70mg/dl; time with severe hypoglycemia: \<54mg/dl assessed by CGM.

    Time frame: 14 days

  4. Mean glucose levels

    Mean glucose levels during monitoring period assessed by CGM.

    Time frame: 14 days

  5. Glucose variability

    Glucose variability during monitoring period assessed by CGM.

    Time frame: 14 days

  6. Correlation between severity of hypoglycemia during ogtt and hypoglycemia in everyday life

    Correlation between severity of hypoglycemia during OGTT and incidence and severity of hypoglycemia in everyday life assessed by CGM.

    Time frame: Varying time point between oGTT and 14 days of glucose assessment using CGM

  7. Correlation between body composition and hypoglycemia in everyday life

    Correlation between body composition (assessed by bioelectrical impedance analysis and anthropometric measurements) and incidence as well as severity of hypoglycemia in everyday life assessed by CGM.

    Time frame: 14 days

07

Study locations

1 site
  • Universityhospital Ulm
    Ulm, 89081, Germany
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06182527
Lead sponsor
University of Ulm
Responsible party
Martin Heni (Prof. Martin Heni, University of Ulm) — Principal investigator
First posted
Dec 27, 2023
Start date
Dec 27, 2023
Primary completion
Jul 22, 2025
Completion
Aug 12, 2025
Last update
Dec 10, 2025

Study contacts

Martin Heni, Prof.
principal investigator · University Hospital Ulm

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion